Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL999514 | 0.76 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL30740657 | 0.76 | KDM4E (0.68) | KDM4ECYP2D6CYP2C19BLMNPSR1 | |
| Trifluoromethanesulfonic Acid SCHEMBL5177368 | 0.76 | F2 (0.38) | KDM4ECYP2D6CYP2C19BLMNPSR1 | |
| Iodide SCHEMBL1763605 | 0.74 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL1932986 | 0.74 | CA2 (0.43) | CA1CA2 | |
| Trifluoromethanesulfonic Acid SCHEMBL7320428 | 0.74 | ALDH1A1 (0.41) | KDM4ECYP2D6CYP2C19BLMNPSR1 | |
| Trifluoromethanesulfonic Acid SCHEMBL5092177 | 0.74 | ALDH1A1 (0.45) | KDM4ECYP2D6CYP2C19BLMNPSR1 | |
| Trifluoromethanesulfonic Acid SCHEMBL2240490 | 0.71 | CA2 (0.45) | KDM4ECA1CA2 | |
| Trifluoromethanesulfonic Acid SCHEMBL1750663 | 0.71 | CA2 (0.45) | KDM4ECA1CA2 | |
| Trifluoromethanesulfonic Acid SCHEMBL30662099 | 0.71 | ALDH1A1 (0.47) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007396-B1 | Enfumafungin derivatives as antifungal agents | MERCK SHARP & DOHME (US) | 2013-02-13 | — | — | EP | disclosed |
| US-7863465-B2 | Antifungal agents | MERCK SHARP & DOHME CORP. (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2007396-A1 | ANTIFUNGAL AGENTS | Merck and Co., Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080009504-A1 | Antifungal agents | SCYNEXIS, INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2007127012-A1 | ANTIFUNGAL AGENTS | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009504-A1 | Antifungal agents | DPM1, MAN2B1, MAN2A1 | KDM4E 3462/4885CYP2D6 397/4885CYP2C19 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.